Literature DB >> 9765451

A bipartite membrane-binding signal in the human immunodeficiency virus type 1 matrix protein is required for the proteolytic processing of Gag precursors in a cell type-dependent manner.

Y M Lee1, C J Tian, X F Yu.   

Abstract

It is unclear whether proteolytic processing of the human immunodeficiency virus type 1 (HIV-1) Gag protein is dependent on virus assembly at the plasma membrane. Mutations that prevent myristylation of HIV-1 Gag proteins have been shown to block virus assembly and release from the plasma membrane of COS cells but do not prevent processing of Gag proteins. In contrast, in HeLa cells similar mutations abolished processing of Gag proteins as well as virus production. We have now addressed this issue with CD4(+) T cells, which are natural target cells of HIV-1. In these cells, myristylation of Gag proteins was required for proteolytic processing of Gag proteins and production of extracellular viral particles. This result was not due to a lack of expression of the viral protease in the form of a Gag-Pol precursor or a lack of interaction between unmyristylated Gag and Gag-Pol precursors. The processing defect of unmyristylated Gag was partially rescued ex vivo by coexpression with wild-type myristylated Gag proteins in HeLa cells. The cell type-dependent processing of HIV-1 Gag precursors was also observed when another part of the plasma membrane binding signal, a polybasic region in the matrix protein, was mutated. The processing of unmyristylated Gag precursors was inhibited in COS cells by HIV-1 protease inhibitors. Altogether, our findings demonstrate that the processing of HIV-1 Gag precursors in CD4(+) T cells occurs normally at the plasma membrane during viral morphogenesis. The intracellular environment of COS cells presumably allows activation of the viral protease and proteolytic processing of HIV-1 Gag proteins in the absence of plasma membrane binding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765451      PMCID: PMC110323     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments.

Authors:  A H Kaplan; R Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

2.  Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src.

Authors:  J W Wills; R C Craven; R A Weldon; T D Nelle; C R Erdie
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

3.  Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers.

Authors:  H Burstein; D Bizub; A M Skalka
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

4.  Form, function, and use of retroviral gag proteins.

Authors:  J W Wills; R C Craven
Journal:  AIDS       Date:  1991-06       Impact factor: 4.177

5.  Myristoylation of gag proteins of HIV-1 plays an important role in virus assembly.

Authors:  R Pal; M S Reitz; E Tschachler; R C Gallo; M G Sarngadharan; F D Veronese
Journal:  AIDS Res Hum Retroviruses       Date:  1990-06       Impact factor: 2.205

6.  N myristoylation of the spleen necrosis virus matrix protein is required for correct association of the Gag polyprotein with intracellular membranes and for particle formation.

Authors:  T A Weaver; A T Panganiban
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

7.  Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.

Authors:  H G Göttlinger; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

8.  HIV expression strategies: ribosomal frameshifting is directed by a short sequence in both mammalian and yeast systems.

Authors:  W Wilson; M Braddock; S E Adams; P D Rathjen; S M Kingsman; A J Kingsman
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

9.  Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.

Authors:  M Bryant; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

10.  Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity.

Authors:  H G Kräusslich
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

View more
  12 in total

1.  Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus.

Authors:  A Ono; E O Freed
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts.

Authors:  D H Nguyen; J E Hildreth
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

Authors:  S Sei; Q E Yang; D O'Neill; K Yoshimura; K Nagashima; H Mitsuya
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Nef from human immunodeficiency virus type 1(F12) inhibits viral production and infectivity.

Authors:  O T Fackler; P d'Aloja; A S Baur; M Federico; B M Peterlin
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Formation of virus assembly intermediate complexes in the cytoplasm by wild-type and assembly-defective mutant human immunodeficiency virus type 1 and their association with membranes.

Authors:  Y M Lee; B Liu; X F Yu
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.

Authors:  J T Qiu; B Liu; C Tian; G N Pavlakis; X F Yu
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

7.  Interaction of the human immunodeficiency virus type 1 nucleocapsid with actin.

Authors:  B Liu; R Dai; C J Tian; L Dawson; R Gorelick; X F Yu
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

8.  Association of murine leukemia virus pol with virions, independent of Gag-Pol expression.

Authors:  G L Buchschacher; L Yu; F Murai; T Friedmann; A Miyanohara
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

9.  Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses.

Authors:  J T Qiu; R Song; M Dettenhofer; C Tian; T August; B K Felber; G N Pavlakis; X F Yu
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

10.  Intracellular transport of human immunodeficiency virus type 1 genomic RNA and viral production are dependent on dynein motor function and late endosome positioning.

Authors:  Martin Lehmann; Miroslav P Milev; Levon Abrahamyan; Xiao-Jian Yao; Nelly Pante; Andrew J Mouland
Journal:  J Biol Chem       Date:  2009-03-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.